Incretin therapy: Should adverse consequences have been anticipated?: Transparency is what we need

BMJ (Online)

Volumn 346, Issue 7912, 2013, Pages

  Gale, Edwin ^a  

^a SOUTHMEAD HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

EXENDIN 4; GLITAZONE DERIVATIVE; GLUCAGON LIKE PEPTIDE 1; GLUCAGON LIKE PEPTIDE 1 RECEPTOR; INCRETIN; PIOGLITAZONE; ROSIGLITAZONE; SITAGLIPTIN; TROGLITAZONE;

ACUTE PANCREATITIS; ADVERSE OUTCOME; BLADDER CANCER; CARDIOVASCULAR DISEASE; CLINICAL TRIAL (TOPIC); DIABETES MELLITUS; DRUG EFFECT; DRUG INDUSTRY; DRUG LEGISLATION; DRUG MANUFACTURE; DRUG MARKETING; DRUG SAFETY; DRUG SURVEILLANCE PROGRAM; DRUG WITHDRAWAL; EDITORIAL; FLUID RETENTION; FOOD AND DRUG ADMINISTRATION; HUMAN; LIVER INJURY; NONHUMAN; OSTEOPENIA; PANCREAS DISEASE; PRIORITY JOURNAL; SIDE EFFECT; WEIGHT GAIN;

ANIMALS; GLUCAGON; HUMANS; HYPOGLYCEMIC AGENTS; PANCREATIC DISEASES;

EID: 84879246350     PISSN: None     EISSN: 17561833     Source Type: Journal    
DOI: 10.1136/bmj.f3617     Document Type: Editorial

References (12)

1. Cohen D. Has pancreatic damage from glucagon suppressing drugs been underplayed? BMJ 2013;346:f3680.
2. Gale EAM. Troglitazone. The lesson that nobody learned. Diabetologia 2006;49:1-6. (Pubitemid 43151605)
3. Gale EAM. The second time as farce: rosiglitazone and the regulators. Nat Rev Endocrinol 2011;7:5-6.
4. Calanna S, Christensen M, Holst JJ, Laferrére B, Gluud LL, Vilsbøll T, et al. Secretion of glucagon-like peptide-1 in patients with type 2 diabetes: systematic review and meta-analyses of clinical studies. Diabetologia 2013;56:965-72.
5. Christel CM, DeNardo DF, Secor SM. Metabolic and digestive response to food ingestion in a binge-feeding lizard, the Gila monster (Heloderma suspectum). J Exp Biol 2007;210;3430-9. (Pubitemid 350057241)
6. Singh S, Hsien-Yen Chang, Richard TM, Weiner JP, Clark JM, Segal JB. Glucagon-like peptide 1-based therapies and risk of hospitalization for acute pancreatitis in type 2 diabetes: a population-based matched case-control study. JAMA Intern Med 2013;173:534-9.
7. Perspective on GLP-1 agents for diabetes. Quarterwatch April 2013. www.ismp.org/ Newsletters/acutecare/showarticle.asp?id=46.
8. Butler AE, Campbell-Thompson M, Gurlo T, Dawson DW, Atkinson M, Butler PC. Marked expansion of exocrine and endocrine pancreas with incretin therapy in humans with increased exocrine pancreas dysplasia and the potential for glucagon-producing neuroendocrine tumors. Diabetes 2013; published online 22 Mar.
9. Gale EAM. GLP-1 based agents and acute pancreatitis: drug safety falls victim to the three monkey paradigm. BMJ 2013;346:f1263.
10. Butler PC, Elashoff M, Elashoff R, Gale EAM. A critical analysis of the clinical use of incretin-based therapies: are the GLP-1 therapies safe? Diabetes Care 2013; published online 6 May.
11. Xu R, Dhall D, Nissen NN, Zhou C, Ren S-G. Pancreatic neuroendocrine tumors in glucagon receptor-deficient mice. PLoS One 2011;6:e23397.
12. Habener JF, Stanojevic V. Alpha cells come of age. Trends Endocrinol Metab 2013;24:153-63.